Skip to content

Nefazodone in the Treatment of Cocaine Dependence and Depression - 4

Efficacy of Nefazodone in Cocaine Dependent Subjects

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00015210
Enrollment
69
Registered
2001-04-18
Start date
1997-02-28
Completion date
Unknown
Last updated
2015-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cocaine-Related Disorders, Substance-Related Disorders

Keywords

Cocaine Use Disorders Dependence Depression

Brief summary

The purpose of this study is the use of Nefazodone in the treatment of cocaine dependence and depression comorbidity.

Detailed description

The objective of this study is to determine the safety and efficacy of nefazodone (Serzone ) in depressed cocaine dependent subjects. This is a hypothesis-testing study which will explore whether cocaine usage will be reduced in the nefazodone treatment group compared to a placebo control group.

Interventions

All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.

Sponsors

Boston University
CollaboratorOTHER
Boston Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

DSM-IV diagnosis of cocaine dependence, Depression score of 12 or above and history of depression. Males and non-pregnant, non-nursing females 21-55 years of age.

Exclusion criteria

Axis I diagnosis other than substance use disorder, major depression, anxiety of dysthymic disorder. Physiological dependence on alcohol. Significant medical or neurological history. Abnormal UA, CBC or Chem 23 (LFT's may be up to 3 times normal). Enrollment in an opiate-substitution treatment program within 45 days of enrollment in the present study.

Design outcomes

Primary

MeasureTime frameDescription
Urine benzoylecgonine (BE) concentrationStudy Weeks Basekine to Week 8Natural log BE in urine samples collected weekly were analyzed for the baseline week and the subsequent 8 treatment weeks.

Secondary

MeasureTime frameDescription
Hamilton Depression Scale (HAM-D)Baseline through Study Week 8HAM-D collected on a weekly basis.
Cocaine-Craving ScaleBaseline through Week 8CCS scores were collected on a weekly basis.
Adverse Events Self ReportStudy Weeks 1 through 8Data for adverse events were collected on a weekly basis
Alcohol Drug Use InventoryBaseline through Study Week 8Subjects were asked about the amount of cocaine consumed and the number of days in cocaine was used in the previous week, on a weekly basis.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026